Form 4: Achieve Life Sciences Executive Chairman Awarded Performance-Based Stock Units and Options

Thomas Braxton King, Executive Chairman of Achieve Life Sciences, was granted 455,000 performance-restricted stock units and 195,000 stock options on January 13, 2025.

Summary

• Thomas Braxton King, the Executive Chairman of Achieve Life Sciences, received a grant of 455,000 Performance Restricted Stock Units (PRSUs) and 195,000 stock options on January 13, 2025.
• The PRSUs will vest upon the achievement of certain milestones, and if no milestones are met, the PRSUs will lapse.
• Each PRSU represents a contingent right to receive one share of the company's common stock at settlement.
• The stock options have an exercise price of $3.32 and will vest over a period of 4 years, with 1/4 vesting on the first anniversary of August 26, 2024, and the remainder vesting monthly over the following 36 months, contingent on continued service.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which are generally viewed positively as they align management interests with shareholder value. The performance-based aspect of the PRSUs is a positive sign.

Positives

• The performance-based nature of the PRSUs aligns executive compensation with company goals.
• The vesting schedule of the stock options incentivizes long-term commitment from the Executive Chairman.

Risks

• The PRSUs will lapse if the performance milestones are not achieved, potentially leading to a loss of incentive for the executive.
• The vesting of the stock options is contingent on continued service, which could be a risk if the executive leaves the company.

Industry Context

This type of equity-based compensation is common in the biotechnology industry to align executive interests with shareholder value creation and company performance.

Comparison to Industry Standards

• The use of performance-based restricted stock units (PRSUs) and stock options is a standard practice in the biotech industry for executive compensation.
• Many biotech companies use similar vesting schedules for stock options, typically over a 3-4 year period.
• The specific milestones for the PRSUs would need to be compared to other companies to assess the difficulty and appropriateness of the targets.

Stakeholder Impact

• Shareholders may view the performance-based compensation positively as it aligns executive interests with company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Performance Restricted Stock Units, Stock Options, Executive Compensation, Vesting, Milestones, ACHV, Incentive